Identification of Hemochromatosis Gene Polymorphisms in Chronically Transfused Patients with Sickle Cell Diseases

Michael R. Jeng, Patricia Adams-Graves, Thad A. Howard, Matthew Whorton, Chin Shang Li, Russell E. Ware

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Three polymorphic gene mutations in the human hemochromatosis (HFE) gene (C282Y, H63D, S65C) are associated with non-transfusion-related iron overload in Caucasians. More recently, these mutations have also been identified in African-Americans. However, the prevalence of HFE gene mutations in African-Americans with sickle cell disease (SCD) has not been described. The presence of these mutations in this population is particularly important, because patients with SCD may be placed on chronic red cell transfusion therapy and are thus at further risk for iron overload. Thus, we attempted to establish the gene mutation prevalence in African-Americans with SCD, to compare this frequency with published gene frequencies in African-Americans, and to evaluate their significance with regard to transfusion-related iron overload. Eighty-nine African-American patients with SCD, all of whom were receiving chronic red cell transfusion therapy, were screened by DNA analysis for the three HFE gene mutations. Two patients were heterozygous for the C282Y HFE mutation (2.3%), six were heterozygous for the H63D mutation (6.8%), none carried the S65C mutation (0.0%), and no homozygous or compound heterozygous subjects were identified. The prevalence of C282Y and H63D in the SCD population was similar to that observed in the general African-American population. In addition, there was no increased mutation prevalence when comparing those SCD patients on chronic transfusion therapy who had ferritin levels greater than 2,500 ng/mL and those less than 2,500 ng/mL. This study represents the first identification of the known HFE gene mutations by DNA analysis in the SCD population. We conclude that the presence of recognized HFE coding region mutations do not seem to have an impact on the degree of iron overload in patients with SCD receiving chronic transfusion therapy.

Original languageEnglish (US)
Pages (from-to)243-248
Number of pages6
JournalAmerican Journal of Hematology
Volume74
Issue number4
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Hemochromatosis
Sickle Cell Anemia
Mutation
African Americans
Genes
Iron Overload
Cell- and Tissue-Based Therapy
Population
DNA
Ferritins
Gene Frequency

Keywords

  • Hemochromatosis
  • Iron overload
  • Sickle cell disease

ASJC Scopus subject areas

  • Hematology

Cite this

Identification of Hemochromatosis Gene Polymorphisms in Chronically Transfused Patients with Sickle Cell Diseases. / Jeng, Michael R.; Adams-Graves, Patricia; Howard, Thad A.; Whorton, Matthew; Li, Chin Shang; Ware, Russell E.

In: American Journal of Hematology, Vol. 74, No. 4, 12.2003, p. 243-248.

Research output: Contribution to journalArticle

Jeng, Michael R. ; Adams-Graves, Patricia ; Howard, Thad A. ; Whorton, Matthew ; Li, Chin Shang ; Ware, Russell E. / Identification of Hemochromatosis Gene Polymorphisms in Chronically Transfused Patients with Sickle Cell Diseases. In: American Journal of Hematology. 2003 ; Vol. 74, No. 4. pp. 243-248.
@article{0451a0b5686a4716bd2807843d694fc3,
title = "Identification of Hemochromatosis Gene Polymorphisms in Chronically Transfused Patients with Sickle Cell Diseases",
abstract = "Three polymorphic gene mutations in the human hemochromatosis (HFE) gene (C282Y, H63D, S65C) are associated with non-transfusion-related iron overload in Caucasians. More recently, these mutations have also been identified in African-Americans. However, the prevalence of HFE gene mutations in African-Americans with sickle cell disease (SCD) has not been described. The presence of these mutations in this population is particularly important, because patients with SCD may be placed on chronic red cell transfusion therapy and are thus at further risk for iron overload. Thus, we attempted to establish the gene mutation prevalence in African-Americans with SCD, to compare this frequency with published gene frequencies in African-Americans, and to evaluate their significance with regard to transfusion-related iron overload. Eighty-nine African-American patients with SCD, all of whom were receiving chronic red cell transfusion therapy, were screened by DNA analysis for the three HFE gene mutations. Two patients were heterozygous for the C282Y HFE mutation (2.3{\%}), six were heterozygous for the H63D mutation (6.8{\%}), none carried the S65C mutation (0.0{\%}), and no homozygous or compound heterozygous subjects were identified. The prevalence of C282Y and H63D in the SCD population was similar to that observed in the general African-American population. In addition, there was no increased mutation prevalence when comparing those SCD patients on chronic transfusion therapy who had ferritin levels greater than 2,500 ng/mL and those less than 2,500 ng/mL. This study represents the first identification of the known HFE gene mutations by DNA analysis in the SCD population. We conclude that the presence of recognized HFE coding region mutations do not seem to have an impact on the degree of iron overload in patients with SCD receiving chronic transfusion therapy.",
keywords = "Hemochromatosis, Iron overload, Sickle cell disease",
author = "Jeng, {Michael R.} and Patricia Adams-Graves and Howard, {Thad A.} and Matthew Whorton and Li, {Chin Shang} and Ware, {Russell E.}",
year = "2003",
month = "12",
doi = "10.1002/ajh.10426",
language = "English (US)",
volume = "74",
pages = "243--248",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Identification of Hemochromatosis Gene Polymorphisms in Chronically Transfused Patients with Sickle Cell Diseases

AU - Jeng, Michael R.

AU - Adams-Graves, Patricia

AU - Howard, Thad A.

AU - Whorton, Matthew

AU - Li, Chin Shang

AU - Ware, Russell E.

PY - 2003/12

Y1 - 2003/12

N2 - Three polymorphic gene mutations in the human hemochromatosis (HFE) gene (C282Y, H63D, S65C) are associated with non-transfusion-related iron overload in Caucasians. More recently, these mutations have also been identified in African-Americans. However, the prevalence of HFE gene mutations in African-Americans with sickle cell disease (SCD) has not been described. The presence of these mutations in this population is particularly important, because patients with SCD may be placed on chronic red cell transfusion therapy and are thus at further risk for iron overload. Thus, we attempted to establish the gene mutation prevalence in African-Americans with SCD, to compare this frequency with published gene frequencies in African-Americans, and to evaluate their significance with regard to transfusion-related iron overload. Eighty-nine African-American patients with SCD, all of whom were receiving chronic red cell transfusion therapy, were screened by DNA analysis for the three HFE gene mutations. Two patients were heterozygous for the C282Y HFE mutation (2.3%), six were heterozygous for the H63D mutation (6.8%), none carried the S65C mutation (0.0%), and no homozygous or compound heterozygous subjects were identified. The prevalence of C282Y and H63D in the SCD population was similar to that observed in the general African-American population. In addition, there was no increased mutation prevalence when comparing those SCD patients on chronic transfusion therapy who had ferritin levels greater than 2,500 ng/mL and those less than 2,500 ng/mL. This study represents the first identification of the known HFE gene mutations by DNA analysis in the SCD population. We conclude that the presence of recognized HFE coding region mutations do not seem to have an impact on the degree of iron overload in patients with SCD receiving chronic transfusion therapy.

AB - Three polymorphic gene mutations in the human hemochromatosis (HFE) gene (C282Y, H63D, S65C) are associated with non-transfusion-related iron overload in Caucasians. More recently, these mutations have also been identified in African-Americans. However, the prevalence of HFE gene mutations in African-Americans with sickle cell disease (SCD) has not been described. The presence of these mutations in this population is particularly important, because patients with SCD may be placed on chronic red cell transfusion therapy and are thus at further risk for iron overload. Thus, we attempted to establish the gene mutation prevalence in African-Americans with SCD, to compare this frequency with published gene frequencies in African-Americans, and to evaluate their significance with regard to transfusion-related iron overload. Eighty-nine African-American patients with SCD, all of whom were receiving chronic red cell transfusion therapy, were screened by DNA analysis for the three HFE gene mutations. Two patients were heterozygous for the C282Y HFE mutation (2.3%), six were heterozygous for the H63D mutation (6.8%), none carried the S65C mutation (0.0%), and no homozygous or compound heterozygous subjects were identified. The prevalence of C282Y and H63D in the SCD population was similar to that observed in the general African-American population. In addition, there was no increased mutation prevalence when comparing those SCD patients on chronic transfusion therapy who had ferritin levels greater than 2,500 ng/mL and those less than 2,500 ng/mL. This study represents the first identification of the known HFE gene mutations by DNA analysis in the SCD population. We conclude that the presence of recognized HFE coding region mutations do not seem to have an impact on the degree of iron overload in patients with SCD receiving chronic transfusion therapy.

KW - Hemochromatosis

KW - Iron overload

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=0345306730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345306730&partnerID=8YFLogxK

U2 - 10.1002/ajh.10426

DO - 10.1002/ajh.10426

M3 - Article

C2 - 14635204

AN - SCOPUS:0345306730

VL - 74

SP - 243

EP - 248

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -